Amoxicillin And Clavulanate Potassium

Introduction Overview

Generic Name

amoxicillin and clavulanate potassium

Brand Name

Augmentin

Dosage Form

Oral tablets (immediate-release and extended-release), oral suspension (liquid)

Drug Class

Penicillins / beta-lactamase inhibitors

Pharmacokinetics

Absorption

Amoxicillin and clavulanate potassium are both well absorbed from the gastrointestinal tract after oral administration. Amoxicillin exhibits rapid and almost complete absorption, with bioavailability exceeding 90% when taken on an empty stomach, although the presence of food can delay the rate but not the extent of absorption, which may improve gastrointestinal tolerability. Clavulanate potassium is also efficiently absorbed, with bioavailability ranging between 60-70%. Food can affect clavulanate’s absorption by slowing it, often leading to recommendations that the drug be taken at the start of a meal to optimize absorption and decrease gastric irritation. The absorption kinetics are influenced by the formulation, with extended-release formulations designed to improve plasma concentrations over a longer period. Both components readily reach therapeutic plasma levels essential for antibacterial activity.

Distribution

Following absorption, amoxicillin distributes widely into body tissues and fluids, including respiratory tract tissues, sinuses, middle ear, and urinary tract, which supports its broad clinical utility. Volume of distribution of amoxicillin approximates total body water (about 0.3 L/kg). Clavulanate potassium similarly distributes into various tissues but with slightly lower penetration. Both drugs cross the placenta and are detected in breast milk, which necessitates caution in pregnancy and lactation. Protein binding is low: approximately 17-20% for amoxicillin and about 25% for clavulanate potassium, resulting in a significant free drug fraction that is pharmacologically active. Distribution is generally not altered significantly in patients with mild to moderate organ impairment.

Metabolism

Amoxicillin is minimally metabolized in humans; it remains largely unchanged and active in systemic circulation. Clavulanate potassium undergoes partial metabolism hepatic ally and extrahepatically, with metabolites identified in urine and feces. The metabolic pathways of clavulanate involve hydrolysis and oxidative processes but the metabolites generally lack antibacterial activity. The differences in metabolic properties of the two components are important clinically, as metabolism plays a role in elimination and potential drug interactions. Neither component undergoes significant cytochrome P450 metabolism, diminishing the likelihood of many common drug interactions.

Elimination

Amoxicillin is primarily eliminated by renal excretion through active tubular secretion and glomerular filtration, with approximately 60-70% of an oral dose recovered unchanged in urine within 6-8 hours. The elimination half-life in patients with normal renal function is approximately 1 hour. Clavulanate potassium exhibits elimination via renal excretion and hepatic clearance; approximately 25-40% of clavulanate is excreted unchanged in urine. Both drugs require dosage adjustment in patients with significant renal impairment to avoid accumulation and toxicity. The elimination kinetics underlie the dosing schedules (usually every 8 to 12 hours) to maintain effective plasma drug concentrations.

Dosage Forms

Adults

Augmentin is available as immediate-release tablets, extended-release tablets, and oral suspensions. Adults typically receive immediate-release tablets of 250 mg/125 mg, 500 mg/125 mg, or 875 mg/125 mg (amoxicillin/clavulanate respectively) every 12 hours or every 8 hours depending on infection severity and site. The extended-release formulation (e.g., 1000 mg/62.5 mg) is given every 12 hours for specific indications such as sinusitis and community-acquired pneumonia. Oral suspensions are dosed based on weight especially in pediatric populations but can be used in adults unable to swallow tablets. The duration typically ranges from 5 to 14 days depending on infection and clinical response.

Adolescents

In adolescents weighing over 40 kg, dosing generally follows adult recommendations. Immediate-release tablets are preferred, with doses ranging from 250 mg/125 mg to 875 mg/125 mg, administered every 12 hours or every 8 hours based on infection type and severity. Oral suspensions may be used for adolescents unable to take tablets, with weight-based dosing. Extended-release formulations are usually limited to adult patients and not routinely recommended for adolescents under 18 years.

Special Populations

In patients with renal impairment, dosage adjustment is necessary; for example, in moderate impairment (creatinine clearance 30-60 mL/min), dosing interval can be extended to every 12 hours or reduced doses. In severe renal disease or dialysis, Augmentin use is contraindicated or requires significant modifications due to drug accumulation. In hepatic impairment, caution is advised because clavulanate potassium has partial hepatic metabolism and can cause liver toxicity. In pregnancy, Augmentin is generally considered safe (FDA pregnancy category B), but use should be based on benefit-risk assessment. Breastfeeding women should use with caution as small amounts are excreted into milk. Pediatric dosing is weight-based, typically 20-45 mg/kg/day of the amoxicillin component divided into two or three doses.

Mechanism Of Action

Augmentin is a combination antibiotic consisting of amoxicillin, a beta-lactam antibiotic, and clavulanate potassium, a beta-lactamase inhibitor. Amoxicillin exerts its antibacterial effect by targeting bacterial cell wall synthesis. It binds irreversibly to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This inhibition impairs the construction of the cell wall, particularly the cross-linking of peptidoglycan polymers, ultimately weakening the cell wall structure and leading to cell lysis via osmotic instability. This mechanism is bactericidal and effective against many gram-positive and some gram-negative organisms. However, bacterial resistance through the production of beta-lactamase enzymes that hydrolyze the beta-lactam ring reduces amoxicillin's efficacy. Clavulanate potassium does not have significant intrinsic antibacterial activity but covalently binds to and irreversibly inhibits a wide spectrum of beta-lactamase enzymes produced by resistant bacteria. This inhibition prevents beta-lactamase from hydrolyzing amoxicillin, effectively restoring amoxicillin’s activity against beta-lactamase–producing organisms, including many Gram-negative bacteria and some resistant strains of Staphylococcus aureus and Haemophilus influenzae. Clinically, this extends the spectrum of amoxicillin to cover otherwise resistant infections. The combination allows treatment of infections caused by bacteria that would otherwise degrade amoxicillin, making Augmentin effective against a wide range of aerobic and anaerobic pathogens. Research supports that clavulanate’s presence significantly decreases minimum inhibitory concentrations (MICs) for resistant strains compared to amoxicillin alone, improving clinical outcomes. Compared to other beta-lactamase inhibitors (e.g., sulbactam or tazobactam), clavulanate has a broad spectrum of beta-lactamase coverage. Furthermore, the pharmacokinetic compatibility between amoxicillin and clavulanate potassium allows co-formulation in fixed-dose preparations enabling convenient oral administration.

Pharmacological Actions

Bactericidal activity due to inhibition of bacterial cell wall synthesis by amoxicillin
Inhibition of beta-lactamase enzymes by clavulanate potassium, protecting amoxicillin from enzymatic degradation
Broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria including beta-lactamase-producing strains
Enhanced efficacy against resistant bacterial strains through combination therapy
Synergistic antibacterial effect from combining a beta-lactam antibiotic with a beta-lactamase inhibitor
Oral bioavailability suitable for outpatient treatment
Effective penetration into respiratory tract, urinary tract, skin, and soft tissue infections
Low protein binding facilitating widespread distribution
Time-dependent killing characteristic typical of beta-lactams
Minimal metabolism, primarily renal excretion facilitating predictable pharmacokinetics

Therapeutic Clinical Uses

Treatment of acute bacterial sinusitis caused by susceptible organisms
Management of community-acquired pneumonia including infections by beta-lactamase-producing bacteria
Treatment of acute otitis media especially in pediatric populations
Therapy of skin and soft tissue infections including cellulitis and animal bite wounds
Management of urinary tract infections caused by susceptible bacteria
Treatment of bronchitis and exacerbations of chronic bronchitis due to bacterial infection
Eradication of Helicobacter pylori as part of combination therapy for peptic ulcer disease (with other agents)
Dental infections including abscesses and prophylaxis in dental procedures with infection risk
Anthrax exposure (prophylaxis or treatment) in certain protocols
Management of mixed aerobic/anaerobic infections due to broad spectrum coverage
Treatment of infections caused by beta-lactamase producing strains resistant to amoxicillin alone

Side Or Adverse Effects

Gastrointestinal disturbances including nausea, vomiting, and diarrhea are common side effects
Hypersensitivity reactions such as rash, pruritus, and urticaria
Serious allergic reactions including anaphylaxis and Stevens-Johnson syndrome in rare cases
Clostridioides difficile-associated diarrhea and pseudomembranous colitis can occur during or after therapy
Elevated liver enzymes indicating possible hepatotoxicity or cholestatic jaundice, especially with prolonged use or high doses
Transient neutropenia, thrombocytopenia, or hemolytic anemia reported in rare cases
Vaginal candidiasis or yeast infections due to alteration of normal flora
Diaper rash in infants as a manifestation of candidal overgrowth
Headache and dizziness reported infrequently
Injection site reactions for parenteral forms (not oral Augmentin)

Precautions

Use cautiously in patients with history of penicillin or cephalosporin allergy due to risk of cross-reactivity
Renal function should be assessed before initiating therapy, with dose adjustments in impairment
Monitoring liver function tests in patients receiving prolonged treatment
Avoid use in patients with mononucleosis due to risk of nonallergic rash
Caution during pregnancy and lactation; benefit-risk evaluation advised
Use with care in patients with gastrointestinal disease, especially colitis
Inform patients about potential for decreased efficacy of hormonal contraceptives and recommend alternative contraception methods
Advise patients to complete the full course of therapy even if symptoms improve
Avoid concomitant use with bacteriostatic antibiotics that may reduce bactericidal effect
Educate regarding signs of serious allergic reactions and when to seek emergency care

Warnings

Do not use in patients allergic to amoxicillin, clavulanate, other penicillins, or cephalosporins due to risk of severe hypersensitivity reactions
Risk of severe liver injury and cholestatic jaundice, particularly with high doses or prolonged therapy; monitor liver enzymes
Use is contraindicated in patients with a history of jaundice or hepatic dysfunction associated with prior use
Not recommended in severe renal impairment or patients on dialysis without adjustment due to toxicity risk
May reduce effectiveness of oral contraceptives; recommend non-hormonal contraception during treatment
Potential for life-threatening hypersensitivity reactions including anaphylaxis
Use caution when switching between tablet formulations (immediate release vs extended-release), as dosing and absorption differ
Can cause Clostridioides difficile-associated diarrhea, which may manifest during or post-therapy
Avoid in patients with history of antibiotic-associated colitis

Contraindications

Known allergy or hypersensitivity to amoxicillin, clavulanate potassium, penicillins, or cephalosporin antibiotics
History of liver dysfunction or jaundice associated with previous amoxicillin/clavulanate therapy
Severe renal impairment, especially patients receiving dialysis without proper dose adjustment
Patients with infectious mononucleosis due to high incidence of morbilliform rash
Concurrent use with other beta-lactam antibiotics unless specifically indicated

Drug Interactions

Reduced efficacy of estrogen-containing oral contraceptives; recommend alternative contraception
Probenecid can decrease renal tubular secretion of amoxicillin leading to increased serum levels
Allopurinol may increase the frequency of skin rash associated with amoxicillin
Anticoagulants like warfarin may have potentiated anticoagulant effects requiring monitoring of INR
Concurrent use with bacteriostatic antibiotics such as tetracyclines may antagonize bactericidal activity of Augmentin
Potential interaction with methotrexate leading to increased toxicity
Augmentin may interfere with urine glucose tests, causing false positive results
Concurrent use with live bacterial vaccines (e.g., typhoid) may inhibit their efficacy
Incompatibility with certain drugs in intravenous formulations (not oral)

Preparations Of The Drug

Immediate-release oral tablets: 250 mg amoxicillin/125 mg clavulanate, 500 mg amoxicillin/125 mg clavulanate, 875 mg amoxicillin/125 mg clavulanate
Extended-release tablets: 1000 mg amoxicillin/62.5 mg clavulanate
Oral liquids (suspensions): various strengths including 200 mg/28.5 mg per 5 mL, 400 mg/57 mg per 5 mL, 600 mg/42.9 mg per 5 mL
Chewable tablets for pediatric use with various amoxicillin/clavulanate ratios
Intravenous formulations are available but not part of standard Augmentin oral use
Different branded formulations such as Augmentin ES-600 and Amoclan with varying amoxicillin/clavulanate ratios